BFA
ALXN

BlackRock Fund Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

BlackRock Fund Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$674M Buy
5,510,165
+362,879
+7% +$44.4M 0.12% 141
2016
Q3 		$631M Buy
5,147,286
+582,338
+13% +$75M 0.13% 131
2016
Q2 		$533M Buy
4,564,948
+135,363
+3% +$19.2M 0.12% 153
2016
Q1 		$617M Sell
4,429,585
-66,503
-1% -$9.76M 0.14% 119
2015
Q4 		$858M Sell
4,496,088
-247,135
-5% -$43.2M 0.2% 80
2015
Q3 		$742M Buy
4,743,223
+10,707
+0.2% +$1.95M 0.19% 77
2015
Q2 		$855M Buy
4,732,516
+640,927
+16% +$111M 0.21% 68
2015
Q1 		$709M Buy
4,091,589
+507,351
+14% +$91.8M 0.17% 91
2014
Q4 		$663M Buy
3,584,238
+215,273
+6% +$39.9M 0.16% 97
2014
Q3 		$559M Sell
3,368,965
-756,502
-18% -$124M 0.16% 101
2014
Q2 		$645M Sell
4,125,467
-709,857
-15% -$112M 0.18% 76
2014
Q1 		$736M Buy
4,835,324
+982,674
+26% +$156M 0.22% 59
2013
Q4 		$512M Buy
3,852,650
+121,448
+3% +$14.6M 0.16% 93
2013
Q3 		$433M Buy
3,731,202
+204,069
+6% +$22.4M 0.15% 105
2013
Q2 		$325M Buy
+3,527,133
New +$340M 0.12% 140

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock Fund Advisors's ALXN Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Alexion Pharmaceuticals (ALXN) stake by 7% in Q4 2016, buying an estimated $44.4M and bringing the position to 5,510,165 shares worth $674M. The position accounts for 0.12% of the portfolio, ranked #141.

BlackRock Fund Advisors first reported a position in ALXN in Q2 2013 and has held it in 15 quarters since. The position peaked at $858M in Q4 2015. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

  • BlackRock Fund Advisors held 5,510,165 shares of Alexion Pharmaceuticals worth $674M as of Q4 2016.
  • BlackRock Fund Advisors bought 362,879 Alexion Pharmaceuticals shares in Q4 2016, an estimated $44.4M.
  • Alexion Pharmaceuticals made up 0.12% of BlackRock Fund Advisors's portfolio in Q4 2016, its #141 holding.
  • BlackRock Fund Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Alexion Pharmaceuticals position peaked at $858M in Q4 2015.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.